Top Markets
#1 Helium Helium +57.25%
#2 Seeker Seeker +36.80%
#3 Pons Pons +26.62%
#4 TENDIES TENDIES +24.40%
#5 Zylo Ecosystem Zylo Ecosystem +24.40%
#6 UnifAI Network UnifAI Network +21.04%
#7 Bounce Bounce +20.57%
#8 Zora Zora +14.78%
#9 DAPPOS DAPPOS +13.42%
#10 ZKsync ZKsync +12.91%
Coin of the day
Helium Helium
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
Philogen S.p.A. Philogen S.p.A.

Philogen S.p.A.

PHIL
Rankning i aktier #10685
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic... Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.
Aktiekurs
$27.76
Senast synkroniserad: 2026-08-28
Marknadsvärde
$801.60M
Förändring (1 dag)
0.21%
Förändring (1 år)
0.65%
Land
IT
Handel Philogen S.p.A. (PHIL)

Kategori

Healthcare
Utdelningshistorik för Philogen S.p.A. (PHIL)
Philogen S.p.A. (aktiens symbol: PHIL) har gjort totalt 0 utdelningsbetalningar.
Summan av alla utdelningar (justerat för aktiesplitar) är: 0.00
Utdelningsavkastning (TTM): 0
Utdelningsbetalningar för Philogen S.p.A. (PHIL) från 2026 till 2026
Årliga utdelningsbetalningar
År Utdelning (justerat för aktiesplitar) Ändra
Inte tillräckligt med data för de angivna datumen.
Lista över alla utdelningsbetalningar
År Utdelning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningar för liknande företag eller konkurrenter
Företag Antal utdelningsbetalningar Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH